Loading [Contrib]/a11y/accessibility-menu.js
ISSN: 2327-2236

Journal of Health Economics and Outcomes Research

Endocrine Diseases
November 12, 2024 EDT
We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?
Rebecca SmithSamara EisenbergAaron Turner-PfiferJacqueline LeGrandSarah PincusYousra OmerFei WangBruce Pyenson
Healthcare claims data sets were used to estimate the current US population with T1DM and investigate geographic nuances in prevalence and incidence, patient demographics, insurance coverage, and device use.

Recent blog posts

Tracking vampire worms with machine learning − using AI to diagnose schistosomiasis before the parasites causing it hatch in your blood
Tracking vampire worms with machine learning − using AI to diagnose schistosomiasis before the parasites causing it hatch in your blood
Schistosomiasis, a neglected tropical disease, affects over 200 million people and causes 280,000 deaths every year. It's contracted through contaminated water.
Employers Haven’t a Clue How Their Drug Benefits Are Managed
Employers Haven’t a Clue How Their Drug Benefits Are Managed
Employers are "often underequipped, underresourced, and oftentimes not understanding the severity of the lack of oversight and accountability.”
View All Posts
Infectious Diseases
November 05, 2024 EDT
Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023)
Jean JouryNawal Al KaabiSara Al DallalBassam MahboubMostafa ZayedMohamed AbdelazizJennifer Onwumeh-OkwunduMark A. FletcherSubramanyam KumaresanBadarinath C. RamachandracharMohamed Farghaly

This study assessed the epidemiology, seasonality, comorbidities, treatment patterns, length of hospital stay, healthcare resource utilization, and costs associated with pediatric RSV infection in Dubai, UAE.

Other Conditions
November 04, 2024 EDT
Assessing the Fiscal Burden of Overweight and Obesity in Japan through Application of a Public Economic Framework
Ataru IgarashiCillian CopelandNikos KotsopoulosRiku OtaSilvia CapucciDaisuke Adachi

This analysis assesses the fiscal consequences of overweight and obesity in Japan by capturing obesity-attributable lost tax revenue and increased government transfers using a government perspective.

Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes Other Conditions
November 04, 2024 EDT
Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes
Noelle N. GronroosCaroline SwiftMonica S. FrazerAndrew SargentMichael LeszkoErin BuysmanSara AlvarezTyler J. DunnJosh Noone

This article describes patient characteristics and HbA1c changes for patients prescribed a 1.0 mg maintenance dose of Injectable once-weekly semaglutide for diabetes.

Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia Neurological Disorders
October 29, 2024 EDT
Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia
Christie TeiglandZulkarnain PulunganDavid BruhnSteve Hwang

This retrospective analysis evaluated baseline characteristics, healthcare resource utilization, and costs among patients with agitation in Alzheimer dementia and those without agitation in Alzheimer dementia.

Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer Oncology
October 28, 2024 EDT
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer
Franklin D. GaylisBruno EmondAmeur M. ManceurAnabelle Tardif-SamsonLaura MorrisonDominic PilonPatrick LefebvreLorie A. EllisHiremagalur BalajiAndrea Ireland

This study evaluated the adequacy of first-line intravesical BCG treatment among high-risk NMIBC patients in the United States, including the subgroup with carcinoma in situ (CIS) of the bladder.

Neurological Disorders
October 28, 2024 EDT
Costs of Potential Medication Wastage Due to Switching Treatment Among People With Multiple Sclerosis
Darin T. OkudaAchal PatelRobert SchuldtIbraheem AbioyeNicole G. Bonine

We estimated the cost associated with potential medication wastage in a U.S. subcohort of people with multiple sclerosis receiving FDA-approved disease-modifying therapies who switched therapies in a calendar year.

Genetic Disorders
October 18, 2024 EDT
Patient Experience of Living With Hemophilia A: A Conceptual Model of Humanistic and Symptomatic Experience in Adolescents, Adults, and Children
Zalmai HakimiRakhee GhelaniLinda BystrickáNana KraghPatrick MarquisJameel NazirNadine McGale

This aim of this qualitative study is to address the humanistic and symptomatic experience of patients living with hemophilia A and the impact of this condition on quality of life.

Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis Nephrologic/Hepatologic Conditions
September 25, 2024 EDT
Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis
Onur BaserGabriela SamayoaNehir YaparErdem Baser

This study identified patients in the Veterans Affairs health system who likely had undiagnosed NASH using a machine learning algorithm.

Health-Related Quality-of-Life Utility Values in Adults With Late-Onset Pompe Disease: Analyses of EQ-5D Data From the PROPEL Clinical Trial Genetic Disorders
September 18, 2024 EDT
Health-Related Quality-of-Life Utility Values in Adults With Late-Onset Pompe Disease: Analyses of EQ-5D Data From the PROPEL Clinical Trial
Alasdair MacCullochAlison GriffithsNeil JohnsonSimon Shohet

This analysis of EQ-5D health-related quality-of-life utility data from the PROPEL clinical trial compared cipaglucosidase alfa plus miglustat vs alglucosidase alfa plus placebo in late-onset Pompe disease.

Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result Oncology
September 17, 2024 EDT
Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result
Michael J. MorrisSheila A. HabibMaggie L. Do ValleJohn E. Schneider

We evaluate potential cost savings for US payers of CyPath® Lung, a novel diagnostic tool utilizing flow cytometry and machine learning, for the early detection of lung cancer.

Economic Evaluation of a Novel Treatment of Attention-Deficit/Hyperactivity Disorder in US Motor Vehicle Drivers Neurological Disorders
September 17, 2024 EDT
Economic Evaluation of a Novel Treatment of Attention-Deficit/Hyperactivity Disorder in US Motor Vehicle Drivers
Jacie T. CooperJohn E. SchneiderJim PotenzianoDavid S. Fam

We evaluated the economic benefits attributable to improved driving abilities and avoided crashes in patients taking Dyanavel XR compared with patients treated with standard of care or who were untreated.